drug_type
RELEVANT_DRUG
intervention_type
Genetically modified cellular immunotherapy (CAR T cells)
drug_description
Allogeneic T cells engineered with an anti-CD7 chimeric antigen receptor to selectively eliminate CD7-expressing lymphocytes (T cells and some NK cells), providing deep lymphodepletion and immunosuppression prior to transplant in severe aplastic anemia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor T cells are genetically engineered to express an anti-CD7 chimeric antigen receptor. Upon binding CD7 on T cells (and some NK cells), the CAR redirects cytotoxic killing to deplete CD7-positive lymphocytes, inducing deep lymphodepletion and immunosuppression to remove autoreactive T cells and facilitate engraftment prior to allo-HSCT in severe aplastic anemia.
drug_name
Donor-derived CD7 CAR-T cells
nct_id_drug_ref
NCT06633328